Drug Profile
Research programme: ramipril formulations - King Pharmaceuticals/Arrow International
Alternative Names: ramipril formulations - King/ArrowLatest Information Update: 03 Mar 2011
Price :
$50
*
At a glance
- Originator Arrow International
- Developer Pfizer
- Class
- Mechanism of Action ACE inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Phase Unknown Hypertension
Most Recent Events
- 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
- 20 Feb 2006 Investigation in Hypertension in USA (unspecified route)